Mechanisms of 5HT2A Receptor Desensitization

5HT2A受体脱敏机制

• 批准号: 7462079
• 负责人: Nancy A Muma
• 金额: $ 32.36万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7462079
• 关键词: ADRBK1 gene; Agonist; Animals; Antidepressive Agents; Antipsychotic Agents; Anxiety; Binding; Bipolar Disorder; Boxing; Brain; Calcium; Calmodulin; Cell Line; Cells; Chronic; Cultured Cells; Data; Disease; Dose; Enzymes; Figs - dietary; Fluoxetine; Funding; GTP-Binding Proteins; Gene Expression; Genetic Transcription; Goals; Grant; Gray unit of radiation dose; HTR2A gene; Human; Individual; Janus kinase; Lead; Mediating; Mental Depression; Mental disorders; Modeling; Modification; Molecular; Molecular Biology; Monomeric GTP-Binding Proteins; Neurosecretory Systems; Nuclear; Numbers; Pathway interactions; Pharmaceutical Preparations; Pharmacotherapy; Phosphatidylinositol 4,5-Diphosphate; Phosphorylation; Phosphotransferases; Post-Translational Protein Processing; Protein Kinase C; Proteins; Public Health; Purpose; RGS Proteins; Rattus; Receptor Signaling; Refractory; STAT protein; Schizophrenia; Second Messenger Systems; Serotonin; Serotonin Receptor 5-HT2A; Serotonin Receptor 5-HT2C; Signal Pathway; Signal Transduction; Signal Transduction Pathway; Signaling Protein; Synapses; System; Testing; Therapeutic; Therapeutic Intervention; Transglutaminases; Translations; atypical antipsychotic; base; crosslink; desensitization; in vivo; indexing; neuroadaptation; neuropsychiatry; novel; novel strategies; olanzapine; protein expression; receptor; research study; response; second messenger; transcription factor; transglutaminase 1; uptake

DESCRIPTION (provided by applicant): The long-term goal of our studies is to identify the molecular mechanisms of desensitization of serotonin 2A (5-HT2A) receptor signaling. Adaptive changes in post-synaptic 5-HT2A receptor signaling underlie the mechanism of action of several drug treatments for psychiatric disorders including anxiety, schizophrenia, depression, and bipolar disorder. Paradoxically, chronic treatment with both 5-HT2A receptor agonists such as DOI and antagonists including olanzapine desensitize 5-HT2A receptor signaling. Atypical antipsychotics are 5-HT2A receptor antagonists, and although these drugs are widely used, significant numbers of individuals are refractory to drug therapy. To help to resolve this paradox and identify novel targets that regulate 5-HT2A receptor signaling, we plan to investigate the mechanisms by which 5-HT2A receptor signaling is desensitized. We will examine the mechanisms of desensitization of 5-HT2A receptor signaling induced with 5-HT2A receptor agonists (Aim 1), and 5-HT2A receptor antagonists (Aim 2) in cells in culture and in vivo. Our central hypothesis is that agonists induce post-translation modifications while antagonists induce transcriptional changes to cause adaptational changes in 5-HT2A receptor signaling. We will build on our preliminary findings that 5-HT2A receptor agonists induce post- translational modifications to G proteins while chronic treatment with a 5-HT2A receptor antagonist increases RGS7 protein expression via increases in JAK/STAT signaling (STAT being a transcription factor). In addition to modern molecular biology approaches, we use neuroendocrine responses to 5-HT2A receptor-stimulation as an index of desensitization of 5-HT2A receptor signaling in vivo. A major advantage of the neuroendocrine challenge tests is that the results obtained in experimental animals can be rapidly applied to humans since these tests can be performed in humans. Ultimately the purpose of these studies is to identify new targets for therapeutic intervention for psychiatric disorders currently treated with drugs that alter 5-HT2A receptor signaling. By understanding the mechanisms involved in signaling and neuroadaptation, new approaches can be developed to reduce the delay in therapeutic response with antipsychotic and antidepressant therapies and treat individuals refractory to current therapies. PUBLIC HEALTH RELEVANCE: Adaptive changes in post-synaptic 5HT2A/2C receptor signaling may underlie the mechanism of action of several drug treatments for neuropsychiatric. For example, several antipsychotic drugs, such as olanzapine, desensitize both 5-HT2A and 5-HT2C receptors while 5- HT uptake blockers alter the efficacy of 5-HT2A receptor signaling. However, the molecular mechanisms that underlie these adaptive changes in 5-HT2A receptor signaling are not well understood. The purpose of this proposal is to determine the mechanisms involved in the adaptational responses to 5-HT2A receptor agonists and antagonists. By discovering the molecular mechanisms underlying signaling and desensitization of 5-HT2A receptor signaling, new targets for therapeutic intervention will be identified.

描述（由申请人提供）：我们研究的长期目标是确定5-羟色胺2A（5-HT 2A）受体信号转导脱敏的分子机制。突触后5-HT 2A受体信号传导的适应性变化是几种药物治疗精神障碍（包括焦虑症、精神分裂症、抑郁症和双相情感障碍）的作用机制的基础。奇怪的是，用5-HT 2A受体激动剂如DOI和拮抗剂包括奥氮平的长期治疗使5-HT 2A受体信号传导脱敏。非典型抗精神病药是5-HT 2A受体拮抗剂，尽管这些药物被广泛使用，但大量个体对药物治疗是难治的。为了帮助解决这一矛盾，并确定新的目标，调节5-HT 2A受体信号，我们计划调查的机制，5-HT 2A受体信号脱敏。我们将研究5-HT 2A受体激动剂（Aim 1）和5-HT 2A受体拮抗剂（Aim 2）在培养和体内细胞中诱导的5-HT 2A受体信号转导的脱敏机制。我们的中心假设是激动剂诱导翻译后修饰，而拮抗剂诱导转录变化，导致适应性变化的5-HT 2A受体信号转导。我们将基于我们的初步发现，即5-HT 2A受体激动剂诱导G蛋白的翻译后修饰，而用5-HT 2A受体拮抗剂的长期治疗通过JAK/STAT信号传导（STAT是转录因子）的增加来增加RGS 7蛋白表达。除了现代分子生物学方法之外，我们还使用对5-HT 2A受体刺激的神经内分泌反应作为体内5-HT 2A受体信号传导脱敏的指标。神经内分泌激发试验的一个主要优点是，在实验动物中获得的结果可以迅速应用于人类，因为这些试验可以在人类中进行。这些研究的最终目的是确定目前用改变5-HT 2A受体信号的药物治疗的精神疾病的治疗干预的新靶点。通过了解信号传导和神经适应的机制，可以开发新的方法来减少抗精神病药和抗抑郁药治疗的治疗反应延迟，并治疗目前治疗难治的个体。公共卫生关系：突触后5 HT 2A/2C受体信号传导的适应性变化可能是几种神经精神药物治疗的作用机制的基础。例如，几种抗精神病药物，如奥氮平，使5-HT 2A和5-HT 2C受体脱敏，而5- HT摄取阻断剂改变5-HT 2A受体信号传导的功效。然而，5-HT 2A受体信号传导中这些适应性变化的分子机制尚未完全了解。本提案的目的是确定对5-HT 2A受体激动剂和拮抗剂的适应性反应所涉及的机制。通过发现5-HT 2A受体信号传导和脱敏的分子机制，将确定治疗干预的新靶点。